PRIME status for Orchard’s gene therapy
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form of beta-thalassemia.
Read More
Tag: Orchard
GSK hands rare disease gene therapies over to Orchard
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
Read More
Orchard’s ‘bubble baby’ therapy awarded PIM status
UK regulators have awarded Orchard Therapeutics’ experimental ‘bubble baby’ disease therapy OTL-101 Promising Innovative Medicine status, pushing the drug closer to being accepted onto the Early Access to Medicines Scheme.
Read More
UK biotechs link in gene therapy deal
Oxford BioMedica has secured a collaboration and license agreement with fellow UK biotech Orchard Therapeutics centred on developing gene therapies for orphan diseases.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
